Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6500
    +0.0012 (+0.18%)
     

  • OIL

    82.89
    -0.47 (-0.56%)
     

  • GOLD

    2,334.70
    -7.40 (-0.32%)
     

  • Bitcoin AUD

    98,850.74
    -3,620.28 (-3.53%)
     

  • CMC Crypto 200

    1,381.92
    -42.18 (-2.97%)
     

  • AUD/EUR

    0.6072
    +0.0015 (+0.25%)
     

  • AUD/NZD

    1.0948
    +0.0018 (+0.16%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,508.45
    +36.98 (+0.21%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,443.01
    -60.68 (-0.16%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

Lumos Pharma to Participate in Upcoming Investor Conferences

Lumos Pharma, Inc.
·2-min read
Lumos Pharma, Inc.
Lumos Pharma, Inc.

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferences:

Event:

H.C. Wainwright 2022 Global Investment Conference – May 23rd – 26th

Presentation:

Live presentation May 25th at 4:00 – 4:30 PM EDT

Webcast link:

Here

Event:

Jefferies Healthcare Conference – June 8th – 10th

Presentation:

Live fireside chat June 8th at 3:30 – 3:55 PM EDT

Webcast link:

Here

The webcasts for each presentation can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section where a replay of each presentation will be also be available. Please contact your H.C. Wainwright or Jefferies salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conferences or thereafter.

ADVERTISEMENT

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.